Survival trends in patients with gastric and esophageal adenocarcinomas: A population-based study

Mayo Clinic Proceedings

Volumn 83, Issue 10, 2008, Pages 1087-1094

  Crane, Sarah J ^a   Locke III, G Richard ^a   Harmsen, William S ^a   Zinsmeister, Alan R ^a   Romero, Yvonne ^a   Talley, Nicholas J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; POPULATION RESEARCH; RURAL AREA; STOMACH ADENOCARCINOMA; SURVIVAL TIME; URBAN AREA; ADENOCARCINOMA; COMPARATIVE STUDY; ESOPHAGUS TUMOR; FOLLOW UP; HEALTH SURVEY; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL RATE; TIME; UNITED STATES;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MINNESOTA; NEOPLASM STAGING; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 54049114274     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.10.1087     Document Type: Article

References (32)

1. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002;11(2):235-256.
2. Locke GR III, Talley NJ, Carpenter HA, Harmsen WS, Zinsmeister AR, Melton LJ III. Changes in the site- and histology-specific incidence of gastric cancer during a 50-year period. Gastroenterology. 1995;109(6):1750-1756.
3. National Cancer Institute. Estimated new cancer cases and deaths for 2007. In: SEER Cancer Statistics Review 1975-2004. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2004/results_single/ sect_01_table.01.pdf. Accessed August 20, 2008.
4. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265(10):1287-1289.
5. Crane SJ, Locke GR III, Harmsen WS, et al. The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site. Aliment Pharmacol Ther. 2007;25(4):447-453.
6. Murphy SJ, Dickey W, Hughes D, O'Connor FA. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland. Eur J Gastroenterol Hepatol. 2005;17(10):1029-1035.
7. McKian KP, Miller RC, Cassivi SD, Jatoi A. Curing patients with locally advanced esophageal cancer: an update on multimodality therapy. Dis Esophagus. 2006;19(6):448-453.
8. Dalrymple-Hay MJ, Evans KB, Lea RE. Oesophagectomy for carcinoma of the oesophagus and oesophagogastric junction. Eur J Cardiothorac Surg. 1999;15(5):626-630.
9. Jensen LS, Pilegaard HK, Puho E, Pahle E, Melsen NC. Outcome after transthoracic resection of carcinoma of the oesophagus and oesophagogastric junction. Scand J Surg. 2005;94(3):191-196.
10. Cunningham D, Allum WH, Stenning SP, et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
11. Bosset JF, Lorchel F, Mantion G, et al. Radiation and chemoradiation therapy for esophageal adenocarcinoma. J Surg Oncol. 2005;92(3):239-245.
12. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185(6):538-543.
13. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71(3):266-274.
14. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993;104(2):510-513.
15. US Census Bureau. Fact sheet: Olmsted County, Minnesota. US Census Bureau Web site. http://factfinder.census.gov/servlet/ACSSAFFFacts?_event= Search&geo_id=&_geoContext=&_street=&_county= olmsted&_cityTown=olmsted&_state=04000US27&_zip=&_lang= en&_sse=on&pctxt=fph&pgsl=010. 2006. Accessed August 20, 2008.
16. Yamada T, Alpers DH. Textbook of Gastroenterology. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
19. Hansson LE, Sparen P, Nyren O. Survival in stomach cancer is improving: results of a nationwide population-based Swedish study. Ann Surg. 1999;230(2):162-169.
20. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Aliment Pharmacol Ther. 2003;17(5):655-664.
21. Arisue T, Tamura K, Tebayashi A. End results of gastric cancer detected by mass survey: analysis using the relative survival rate curve [in Japanese]. Gan To Kagaku Ryoho. 1998;15(4, pt 2-1):929-936.
22. Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol. 2002;37(12):1359-1365.
23. Faivre J, Forman D, Esteve J, Gatta G; EUROCARE Working Group. Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer. 1998;34(14):2167-2175.
24. Bouvier AM, Binquet C, Gagnaire A, Jouve JL, Faivre J, Bedenne L. Management and prognosis of esophageal cancers: has progress been made? Eur J Cancer. 2006 Jan;42(2):228-233. Epub 2005 Dec 7.
25. Sihvo EI, Luostarinen ME, Salo JA. Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis. Am J Gastroenterol. 2004;99(3):419-424.
26. Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol. 2004;99(4):582-588.
27. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [published correction appears in N Engl J Med. 1999;341(5):384]. N Engl J Med. 1996;335(7):462-467.
28. Shah MA, Kelsen DP. Combined modality therapy of esophageal cancer: changes in the standard of care [editorial]? Ann Surg Oncol. 2004 Jul;11 (7):641-643. Epub 2004 Jun 14.
29. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53(7):925-930.
30. Crosby TD, Brewster AE, Borley A, et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90(1):70-75.
31. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005 Jul 1;23(19):4330-4337. Epub 2005 Mar 21.
32. Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice [editorial]. Ann Surg Oncol. 2007 Oct;14(10):2687-2690. Epub 2007 Jul 27.